Neoadjuvant immunotherapy in primary and metastatic colorectal cancer

A Kanani, T Veen, K Søreide - British Journal of Surgery, 2021 - academic.oup.com
Background Colorectal cancer (CRC) is the second most common solid organ cancer.
Traditional treatment is with surgery and chemotherapy. Immunotherapy has recently …

Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of geriatric surgery), SIFIPAC (Italian Society of …

M Podda, P Sylla, G Baiocchi, M Adamina… - World Journal of …, 2021 - Springer
Background and aims Although rectal cancer is predominantly a disease of older patients,
current guidelines do not incorporate optimal treatment recommendations for the elderly and …

The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local …

LM Fernandez, GP São Julião… - Diseases of the Colon …, 2023 - journals.lww.com
BACKGROUND: Nearly 30% of patients with rectal cancer develop local regrowth after initial
clinical complete response managed by watch and wait. These patients might be at higher …

Delivery of engineered primary tumor-derived exosomes effectively suppressed the colorectal cancer chemoresistance and liver metastasis

C Huang, Y Zhou, X Feng, J Wang, Y Li, X Yao - ACS nano, 2023 - ACS Publications
Liver metastasis is one of the major causes of colorectal cancer (CRC)-related morbidity and
mortality. Delivering small interfering RNAs (siRNAs) or noncoding RNAs has been reported …

The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer 2023 supplement

SJ Langenfeld, BR Davis, JD Vogel… - Diseases of the Colon …, 2024 - journals.lww.com
(ASCRS) is dedicated to ensuring high-quality patient care by advancing the science,
prevention, and management of disorders and diseases of the colon, rectum, and anus. The …

Clinical characteristics and survival analysis of colorectal cancer in China: a retrospective cohort study with 13,328 patients from southern China

L Fang, Z Yang, M Zhang, M Meng, J Feng… - Gastroenterology …, 2021 - academic.oup.com
Background Colorectal cancer (CRC) is one of the most common cancers in China.
However, detailed clinical characteristics and survival information are limited. This study …

Endoscopic predictors of residual tumor after total neoadjuvant therapy: a post hoc analysis from the organ preservation in rectal adenocarcinoma trial

H Williams, HM Thompson, ST Lin… - Diseases of the Colon …, 2024 - journals.lww.com
BACKGROUND: Restaging endoscopy plays a critical role in selecting patients with locally
advanced rectal cancer who respond to neoadjuvant therapy for nonoperative management …

Light and shadow of watch-and-wait strategy in rectal cancer: oncological result, clinical outcomes, and cost-effectiveness analysis

V Ferri, E Vicente, Y Quijano, H Duran, E Diaz… - International Journal of …, 2023 - Springer
Background The watch-and-wait (WW) strategy is a potential option for patients with rectal
cancer who obtain a complete clinic response after neoadjuvant therapy. The aim of this …

Advancing Personalized Medicine in the treatment of locally advanced rectal Cancer

FG Sullo, A Passardi, C Gallio, C Molinari… - Journal of Clinical …, 2024 - mdpi.com
Rectal cancer presents a significant burden globally, often requiring multimodal therapy for
locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course …

Total neoadjuvant therapy significantly increases complete clinical response

RL Rettig, BW Beard, JJ Ryoo, S Kulkarni… - Diseases of the Colon …, 2023 - journals.lww.com
BACKGROUND: Increased experience with total neoadjuvant therapy for rectal cancer
suggests significantly more tumor regression and increased rates of complete clinical …